Thermo Fisher Scientific TMO
Price chart
Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.
Community Sentiment on TMO
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Strategy Backtest
Pick a strategy above and run the backtest to see its simulated performance on TMO.
Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.
TMO at a glance
TMO is priced at $694.76 right now, up 2.63% on the session. That puts its market value at $257.42B, 59th largest among the 3753 stocks we cover.
Over a full year the shares have ranged across $434.50 to $712.17, which puts the current price roughly 94% of the way up that band. Holders are ahead 21.7% over twelve months, and up 15.9% across the last three months.
On the chart it holds above both the 50-day ($660.71) and 200-day ($552.61) moving averages; RSI is 55, and the last 30 sessions moved at roughly 31% annualized volatility.
In the quarter ended Sep 2026 the company brought in $12.14B of revenue, up 9.1% from a year earlier, with $1.73B of net profit (a 14.9% margin).
The stock changes hands at 36.6 times trailing earnings, 16% above its five-year average of 31.7. The median for its industry group is 25.0.
15 analysts follow the stock and the average call is "buy". The mean target, $777.93, sits 12.0% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
BeStock Grade
Composite of 4 factors below, ranked against the 3741 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Higher trailing yield than most of BeStock’s coverage scores higher.
Trading closer to its 52-week high than most peers scores higher.
15 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
BeStock Momentum
TMO is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-12-28, the strategy has returned 437.6% (204.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.
Price forecast
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $777.93, 12.0% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $590.00, so shares trade 17.8% above that estimate. On earnings multiple, it sits in the 88th percentile of its own five-year valuation range (pricier than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Thermo Fisher Scientific: the business
Thermo Fisher Scientific supplies lab instruments, reagents and services to drug companies, hospitals and researchers.
What tends to move it. Biopharma spending and research funding drive orders, and acquisitions add growth.
Where the case gets weaker. Biopharma capital spending pulling back or cuts to government research funding would slow orders for lab instruments and reagents across its customer base, and if acquisitions stop adding growth, the underlying organic trend would be harder to disguise.
Written by hand by the BeStock desk and revised when a business changes. how we work. Spot something out of date? Tell us.
Performance
Price return over each window, from adjusted daily and weekly closes
Technical signals
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | +1.1% | Bullish |
| Price vs 50-day average | +5.2% | Bullish |
| Price vs 200-day average | +25.7% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 54.8 | Bullish |
| MACD (12,26,9) | 9.59 | Bearish |
| Bollinger band position | 64% | Bullish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Key statistics
Quote as of Nov 6, 2026 8:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
How TMO ranks on BeStock
Ranks are among the 3,741 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 36.6x earnings, TMO looks expensive against the market, and trades 46% above the 25.0x median among Infectious Disease names. The two comparisons do not always agree.
TMO stock: common questions
What is TMO's latest share price?
$694.76 is the latest print for TMO, a move of +2.63% against yesterday's close of $676.94. Today's low and high so far: $661.60 and $697.78.
What is TMO worth in total?
Equity value comes to $257.42B at the current price. By that measure it is number 59 of the 3753 names in our coverage.
How is Thermo Fisher Scientific valued against its profits?
Buyers pay 36.6 times the last twelve months of profit (EPS $17.74). Averaged over five years the multiple has been 31.7, and today's level ranks in the 88th percentile of its own history.
What's the 52-week trading range for Thermo Fisher Scientific?
The year's floor is $434.50 and the ceiling $712.17. Shares are 2.4% away from that ceiling.
What's the dividend situation for TMO?
It does. Payouts over the past twelve months work out to a 0.26% yield; the latest ex-dividend date was September 15, 2026.
What are analysts saying about TMO?
Of 15 analysts, 93% say buy, 7% hold and 0% sell. Price targets average $777.93, with the most cautious at $720.00 and the most optimistic at $830.00.
In plain terms, what does Thermo Fisher Scientific sell?
Thermo Fisher Scientific supplies lab instruments, reagents and services to drug companies, hospitals and researchers.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on TMO.